| Display title | Chemistry:Dostarlimab |
| Default sort key | Dostarlimab |
| Page length (in bytes) | 38,138 |
| Namespace ID | 3022 |
| Namespace | Chemistry |
| Page ID | 555287 |
| Page content language | en - English |
| Page content model | wikitext |
| Indexing by robots | Allowed |
| Number of redirects to this page | 0 |
| Counted as a content page | Yes |
| HandWiki item ID | None |
| Edit | Allow all users (infinite) |
| Move | Allow all users (infinite) |
| Page creator | imported>Wincert |
| Date of page creation | 00:10, 6 February 2024 |
| Latest editor | imported>Wincert |
| Date of latest edit | 00:10, 6 February 2024 |
| Total number of edits | 1 |
| Recent number of edits (within past 90 days) | 0 |
| Recent number of distinct authors | 0 |
Description | Content |
Article description: (description)
This attribute controls the content of the description and og:description elements. | Dostarlimab, sold under the brand name Jemperli, is a monoclonal antibody used as an anti-cancer medication for the treatment of endometrial cancer. Dostarlimab is a programmed death receptor-1 (PD-1)–blocking monoclonal antibody.
The most common side effects reported in the US include fatigue/asthenia... |
